BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

On Monday, Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $66.01 which represents a decrease of $-0.59 or -0.89% from the prior close of $66.6. The stock opened at $66.24 ...

BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong ...

BioMarin Pharmaceutical ( BMRN -4.44%), a leader in treatments for rare genetic disorders, released its Q3 2024 earnings on ...

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,590,000 shares ...

Biomarin Pharmaceutical Inc. ( (BMRN) ) has realeased its Q3 earnings. Here is a breakdown of the information Biomarin Pharmaceutical Inc.

Gena Wang, an analyst from Barclays, maintained the Buy rating on BioMarin Pharmaceutical (BMRN – Research Report). The associated price ...

Third Quarter 2024 Results Key Financial Results Revenue: US$745.7m (up ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great ...